160 related articles for article (PubMed ID: 16275075)
1. 5-heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure-activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog.
Sakya SM; DeMello KM; Minich ML; Rast B; Shavnya A; Rafka RJ; Koss DA; Cheng H; Li J; Jaynes BH; Ziegler CB; Mann DW; Petras CF; Seibel SB; Silvia AM; George DM; Lund LA; St Denis S; Hickman A; Haven ML; Lynch MP
Bioorg Med Chem Lett; 2006 Jan; 16(2):288-92. PubMed ID: 16275075
[TBL] [Abstract][Full Text] [Related]
2. 5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers.
Sakya SM; Cheng H; Lundy Demello KM; Shavnya A; Minich ML; Rast B; Dutra J; Li C; Rafka RJ; Koss DA; Li J; Jaynes BH; Ziegler CB; Mann DW; Petras CF; Seibel SB; Silvia AM; George DM; Hickman A; Haven ML; Lynch MP
Bioorg Med Chem Lett; 2006 Mar; 16(5):1202-6. PubMed ID: 16380252
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.
Cheng H; Lundy DeMello KM; Li J; Sakya SM; Ando K; Kawamura K; Kato T; Rafka RJ; Jaynes BH; Ziegler CB; Stevens R; Lund LA; Mann DW; Kilroy C; Haven ML; Nimz EL; Dutra JK; Li C; Minich ML; Kolosko NL; Petras C; Silvia AM; Seibel SB
Bioorg Med Chem Lett; 2006 Apr; 16(8):2076-80. PubMed ID: 16464588
[TBL] [Abstract][Full Text] [Related]
4. Comparative structure-activity relationship studies of 1-(5-methylsulfonylpyrid-2-yl)-5-alkyl and (hetero)aryl triazoles and pyrazoles in canine COX inhibition.
Sakya SM; Shavnya A; Cheng H; Li C; Rast B; Li J; Koss DA; Jaynes BH; Mann DW; Petras CF; Seibel SB; Haven ML; Lynch MP
Bioorg Med Chem Lett; 2008 Feb; 18(3):1042-5. PubMed ID: 18182290
[TBL] [Abstract][Full Text] [Related]
5. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.
Sakya SM; Hou X; Minich ML; Rast B; Shavnya A; DeMello KM; Cheng H; Li J; Jaynes BH; Mann DW; Petras CF; Seibel SB; Haven ML
Bioorg Med Chem Lett; 2007 Feb; 17(4):1067-72. PubMed ID: 17126015
[TBL] [Abstract][Full Text] [Related]
6. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor.
Li J; Lynch MP; Demello KL; Sakya SM; Cheng H; Rafka RJ; Bronk BS; Jaynes BH; Kilroy C; Mann DW; Haven ML; Kolosko NL; Petras C; Seibel SB; Lund LA
Bioorg Med Chem; 2005 Mar; 13(5):1805-9. PubMed ID: 15698798
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.
Fioravanti R; Bolasco A; Manna F; Rossi F; Orallo F; Ortuso F; Alcaro S; Cirilli R
Eur J Med Chem; 2010 Dec; 45(12):6135-8. PubMed ID: 20974503
[TBL] [Abstract][Full Text] [Related]
9. 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.
Singh SK; Vobbalareddy S; Kalleda SR; Rajjak SA; Casturi SR; Datla SR; Mamidi RN; Mullangi R; Bhamidipati R; Ramanujam R; Akella V; Yeleswarapu KR
Org Biomol Chem; 2004 Sep; 2(17):2442-50. PubMed ID: 15326524
[TBL] [Abstract][Full Text] [Related]
10. Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
Caturla F; Amat M; Reinoso RF; Calaf E; Warrellow G
Bioorg Med Chem Lett; 2006 Jul; 16(13):3605-8. PubMed ID: 16647258
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors.
Reddy MV; Billa VK; Pallela VR; Mallireddigari MR; Boominathan R; Gabriel JL; Reddy EP
Bioorg Med Chem; 2008 Apr; 16(7):3907-16. PubMed ID: 18272371
[TBL] [Abstract][Full Text] [Related]
12. Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.
Tsai WJ; Shiao YJ; Lin SJ; Chiou WF; Lin LC; Yang TH; Teng CM; Wu TS; Yang LM
Bioorg Med Chem Lett; 2006 Sep; 16(17):4440-3. PubMed ID: 16814546
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
Shen DM; Brady EJ; Candelore MR; Dallas-Yang Q; Ding VD; Feeney WP; Jiang G; McCann ME; Mock S; Qureshi SA; Saperstein R; Shen X; Tong X; Tota LM; Wright MJ; Yang X; Zheng S; Chapman KT; Zhang BB; Tata JR; Parmee ER
Bioorg Med Chem Lett; 2011 Jan; 21(1):76-81. PubMed ID: 21147532
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; ElTahir KE
Bioorg Med Chem; 2012 May; 20(10):3306-16. PubMed ID: 22516672
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore.
Singh SK; Saibaba V; Rao KS; Reddy PG; Daga PR; Rajjak SA; Misra P; Rao YK
Eur J Med Chem; 2005 Oct; 40(10):977-90. PubMed ID: 15961192
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
Pruitt JR; Pinto DJ; Galemmo RA; Alexander RS; Rossi KA; Wells BL; Drummond S; Bostrom LL; Burdick D; Bruckner R; Chen H; Smallwood A; Wong PC; Wright MR; Bai S; Luettgen JM; Knabb RM; Lam PY; Wexler RR
J Med Chem; 2003 Dec; 46(25):5298-315. PubMed ID: 14640539
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors.
Chen QH; Rao PN; Knaus EE
Bioorg Med Chem; 2005 Dec; 13(23):6425-34. PubMed ID: 16099663
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Navidpour L; Amini M; Shafaroodi H; Abdi K; Ghahremani MH; Dehpour AR; Shafiee A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4483-7. PubMed ID: 16806914
[TBL] [Abstract][Full Text] [Related]
20. Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.
Lin SJ; Tsai WJ; Chiou WF; Yang TH; Yang LM
Bioorg Med Chem; 2008 Mar; 16(5):2697-706. PubMed ID: 18063374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
